Track Aion Therapeutic's EBIT ($-6.3M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jan 31, 2025
Trailing 12 months ending Jan 31, 2025
As of the most recent data (January 2025), ANTCF shows a EBIT of $-6.3M. That compares with $-1M in the prior-year period — down 503.0% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ANTCF's EBIT is now $-6.3M (was $-1M) — a 503.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Aion Therapeutic is outperforming or lagging.
The its sector sector average EBIT is about $2.4T. Aion Therapeutic is at $-6.3M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how ANTCF stacks up against individual peers as well.
Tracking ANTCF's ebit over time shows whether Aion Therapeutic is scaling, shrinking, or reshaping that part of the business. The current reading is $-6.3M That compares with $-1M in the prior-year period — down 503.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Aion Therapeutic's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-6.3M) with ownership activity and broader fundamentals.